Limitations of cellular models in Parkinson's disease research.
暂无分享,去创建一个
[1] Ling Lin,et al. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. , 2005, Human molecular genetics.
[2] C. Ross,et al. α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.
[3] J. Zimmer,et al. Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP+ toxicity by GDNF , 2005, The European journal of neuroscience.
[4] T. Südhof,et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[5] D. Dinsdale,et al. Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosis , 2005, The Journal of cell biology.
[6] J. Paton,et al. Targeting specific neuronal populations using adeno‐ and lentiviral vectors: applications for imaging and studies of cell function , 2005, Experimental physiology.
[7] Á. Almeida,et al. Increased mitochondrial respiration maintains the mitochondrial membrane potential and promotes survival of cerebellar neurons in an endogenous model of glutamate receptor activation , 2005, Journal of neurochemistry.
[8] M. Millan,et al. Involvement of dopamine D2/D3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells , 2004, Experimental Neurology.
[9] Mark R. Segal,et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.
[10] Y. Itoyama,et al. Accelerated α-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells , 2004, Brain Research.
[11] F. Nicoletti,et al. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells , 2003, Journal of neurochemistry.
[12] F. Wouters,et al. Visualization of molecular activities inside living cells with fluorescent labels. , 2004, International review of cytology.
[13] Todd B. Sherer,et al. Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.
[14] S. Bornstein,et al. Combinatorial code of growth factors and neuropeptides define neuroendocrine differentiation in PC12 cells , 2003, Experimental Neurology.
[15] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[16] B. Joseph,et al. Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. , 2003, Experimental cell research.
[17] D. Hernandez,et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. , 2003, Human molecular genetics.
[18] K. Steece-Collier,et al. Cellular Models to Study Dopaminergic Injury Responses , 2003, Annals of the New York Academy of Sciences.
[19] Todd B. Sherer,et al. Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.
[20] D. Perl,et al. Aggresome‐related biogenesis of Lewy bodies , 2002, The European journal of neuroscience.
[21] P. Brundin,et al. Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line* , 2002, The Journal of Biological Chemistry.
[22] A. Wree,et al. Dopaminergic differentiation of the Nurr1‐expressing immortalized mesencephalic cell line CSM14.1 in vitro , 2002, Journal of anatomy.
[23] D. Sulzer,et al. Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.
[24] J. Dichgans,et al. Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. , 2001 .
[25] R. Anwyl,et al. Use-Dependent Effects of Amyloidogenic Fragments of β-Amyloid Precursor Protein on Synaptic Plasticity in Rat Hippocampus In Vivo , 2001, The Journal of Neuroscience.
[26] R. Burke,et al. Synuclein‐1 is selectively up‐regulated in response to nerve growth factor treatment in PC12 cells , 2001, Journal of neurochemistry.
[27] J. Haycock,et al. Synaptic Vesicle Transporter Expression Regulates Vesicle Phenotype and Quantal Size , 2000, The Journal of Neuroscience.
[28] R. Davis,et al. MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). , 1999, Experimental cell research.
[29] D. Mash,et al. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons , 1994, Annals of neurology.
[30] M. Herkenham,et al. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum , 1991, Brain Research.
[31] D. Muller,et al. A simple method for organotypic cultures of nervous tissue , 1991, Journal of Neuroscience Methods.
[32] B. Gähwiler,et al. Organotypic cultures of neural tissue , 1988, Trends in Neurosciences.